Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Viridian gets FDA Breakthrough Tag for TED Therapy Veligrotug
Details : VRDN-001 (veligrotug) is an insulin-like growth factor-1 receptor inhibitor, currently being developed for the treatment of thyroid eye disease.
Product Name : VRDN-001
Product Type : Antibody
Upfront Cash : Inapplicable
May 07, 2025
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Viridian Announces Veligrotug Phase 3 Results for Chronic Thyroid Eye Disease
Details : VRDN-001 (veligrotug) is a differentiated monoclonal antibody targeting IGF-1R. It is being evaluated for the treatment of patients with thyroid eye disease.
Product Name : VRDN-001
Product Type : Antibody
Upfront Cash : Inapplicable
December 16, 2024
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Jefferies
Deal Size : $225.0 million
Deal Type : Public Offering
Viridian Therapeutics Prices Upsized Public Offering of Common and Preferred Stock
Details : The net proceeds will used to fund its clinical development programs, including VRDN-001 (veligrotug), a differentiated monoclonal antibody targeting IGF-1R for the treatment of thyroid eye disease.
Product Name : VRDN-001
Product Type : Antibody
Upfront Cash : Undisclosed
November 09, 2024
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Jefferies
Deal Size : $225.0 million
Deal Type : Public Offering
Lead Product(s) : VRDN-003
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Viridian Therapeutics: Phase 3 Program for VRDN-003 in Thyroid Eye Disease
Details : VRDN-003 is a monoclonal antibody that acts as a full antagonist of IGF-1R, under clinical development for the treatment of Thyroid Eye Disease (TED).
Product Name : VRDN-003
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 06, 2024
Lead Product(s) : VRDN-003
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Viridian Reports Positive Phase 3 Results for Veligrotug in Thyroid Eye Disease
Details : VRDN-001 is a differentiated monoclonal antibody targeting IGF-1R, a clinically and commercially validated target for the treatment of thyroid eye disease.
Product Name : VRDN-001
Product Type : Antibody
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Jefferies
Deal Size : $172.5 million
Deal Type : Public Offering
Viridian Proposes Public Offering of Common and Preferred Stock
Details : The net proceeds will used to fund its clinical development programs, including VRDN-001 (veligrotug), a differentiated monoclonal antibody targeting IGF-1R for the treatment of thyroid eye disease.
Product Name : VRDN-001
Product Type : Antibody
Upfront Cash : Undisclosed
October 09, 2024
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Jefferies
Deal Size : $172.5 million
Deal Type : Public Offering
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Viridian Therapeutics Completes Enrollment for VRDN-001 in Chronic Thyroid Eye Disease
Details : VRDN-001 is a differentiated monoclonal antibody targeting IGF-1R, a clinically and commercially validated target being investigated for the treatment of thyroid eye disease.
Product Name : VRDN-001
Product Type : Antibody
Upfront Cash : Inapplicable
July 25, 2024
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Jefferies
Deal Size : $150.0 million
Deal Type : Public Offering
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
Details : Viridian will use proceeds to advance clinical programs, including VRDN-001, a monoclonal antibody targeting IGF-1R for thyroid eye disease.
Product Name : VRDN-001
Product Type : Antibody
Upfront Cash : Undisclosed
January 17, 2024
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Jefferies
Deal Size : $150.0 million
Deal Type : Public Offering
Lead Product(s) : VRDN-003
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VRDN-003 is a monoclonal antibody that acts as a full antagonist of IGF-1R, a clinically and commercially validated target for TED. It is under phase 1 clinical development for the treatment of Thyroid Eye Disease (TED).
Product Name : VRDN-003
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : VRDN-003
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Fairmount Funds Management LLC
Deal Size : $185.0 million
Deal Type : Private Placement
Details : The financing will be used to expand Viridian’s preclinical portfolio of FcRn inhibitors designed to deliver next generation treatments for patients suffering from antibody-mediated autoimmune diseases including VRDN-001, for patients with TED.
Product Name : VRDN-001
Product Type : Antibody
Upfront Cash : Undisclosed
October 30, 2023
Lead Product(s) : Veligrotug
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Fairmount Funds Management LLC
Deal Size : $185.0 million
Deal Type : Private Placement